Literature DB >> 4027966

Relationships of prostaglandin E and natural killer sensitivity to metastatic potential in murine mammary adenocarcinomas.

A M Fulton, G H Heppner.   

Abstract

The levels of two prostaglandins (prostaglandins E and F) have been determined in a series of murine mammary lesions ranging from preneoplastic, hyperplastic alveolar nodules to highly metastatic adenocarcinomas. A highly positive correlation was seen between high levels of prostaglandin E and high tumorigenicity and metastatic potential. In addition, spontaneous metastasis of two highly metastatic tumors was partially inhibited by p.o. administration of indomethacin from the time of s.c. tumor transplantation until removal of the primary tumor at a limited size. Further, mammary tumor cells of differing metastatic potential were susceptible to polyinosinic-polycytidylic acid activated spleen lymphocytes in vitro. Cells of metastatic tumor lines (410.4 and 66) were more resistant to killing than were cells of two non-metastatic tumor lines (168 and 410). The sensitivity of all target cells was increased when endogenous prostaglandin synthesis was prevented by the addition of indomethacin (1 microM) but was not affected by the lipoxygenase inhibitor nordihydroguaiaretic acid.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4027966

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

1.  Prognostic significance of plasma prostaglandin E concentration in patients with head and neck cancer.

Authors:  I Klapan; V Katić; F Culo; V Cuk
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

2.  Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer.

Authors:  C Costa; R Soares; J S Reis-Filho; D Leitão; I Amendoeira; F C Schmitt
Journal:  J Clin Pathol       Date:  2002-06       Impact factor: 3.411

3.  Frondoside A inhibits breast cancer metastasis and antagonizes prostaglandin E receptors EP4 and EP2.

Authors:  Xinrong Ma; Namita Kundu; Peter D Collin; Olga Goloubeva; Amy M Fulton
Journal:  Breast Cancer Res Treat       Date:  2011-07-15       Impact factor: 4.872

4.  In vitro effects of eicosanoid synthesis inhibitors in the presence of linoleic acid on MDA-MB-231 human breast cancer cells.

Authors:  M Earashi; M Noguchi; M Tanaka
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

5.  Antagonism of the prostaglandin E receptor EP4 inhibits metastasis and enhances NK function.

Authors:  Namita Kundu; Xinrong Ma; Dawn Holt; Olga Goloubeva; Suzanne Ostrand-Rosenberg; Amy M Fulton
Journal:  Breast Cancer Res Treat       Date:  2008-09-16       Impact factor: 4.872

6.  Eicosanoids as mediators of linoleic acid-stimulated invasion and type IV collagenase production by a metastatic human breast cancer cell line.

Authors:  X H Liu; J M Connolly; D P Rose
Journal:  Clin Exp Metastasis       Date:  1996-03       Impact factor: 5.150

7.  Cyclooxygenase and lipoxygenase inhibitors as modulators of cancer therapies.

Authors:  B A Teicher; T T Korbut; K Menon; S A Holden; G Ara
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

8.  Antiproliferative and antiinflammatory coxib-combretastatin hybrids suppress cell cycle progression and induce apoptosis of MCF7 breast cancer cells.

Authors:  Quoc Anh Ngo; Thuy Hang Nguyen Thi; Minh Quan Pham; Domenico Delfino; Thi Thao Do
Journal:  Mol Divers       Date:  2020-06-30       Impact factor: 2.943

9.  Incorporation of polyunsaturated fatty acids into CT-26, a transplantable murine colonic adenocarcinoma.

Authors:  D P Gaposchkin; R A Zoeller; S A Broitman
Journal:  Lipids       Date:  2000-02       Impact factor: 1.646

10.  Amelioration of B16F10 melanoma lung metastasis in mice by a combination therapy with indomethacin and interleukin 2.

Authors:  R S Parhar; P K Lala
Journal:  J Exp Med       Date:  1987-01-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.